Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs

PurposeCirculating cell-free DNA (cfDNA) level has been demonstrated to be associated with efficacy in first generation EGFR TKIs in non-small cell lung cancer (NSCLC). However, the role of dynamic cfDNA analysis using next-generation sequencing (NGS) in patients with subsequent third-generation EGF...

Full description

Bibliographic Details
Main Authors:	Li Ma, Haoyang Li, Dongpo Wang, Ying Hu, Mengjun Yu, Quan Zhang, Na Qin, Xinyong Zhang, Xi Li, Hui Zhang, Yuhua Wu, Jialin Lv, Xinjie Yang, Ruoying Yu, Shucai Zhang, Jinghui Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Oncology
Subjects:	circulating cell-free DNA (cfDNA) EGFR T790M third-generation EGFR TKI declarations lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.643199/full

Similar Items

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
by: José Manuel González de Aledo-Castillo, et al.
Published: (2021-07-01)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
by: Zheng Wang, et al.
Published: (2021-05-01)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
by: Cheng WC, et al.
Published: (2021-01-01)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01)

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
by: Vinh Thanh Tran, et al.
Published: (2020-08-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014-01-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
by: Taira Ninomaru, et al.
Published: (2021-03-01)

A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients
by: Feng Q, et al.
Published: (2018-01-01)

Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Yanxia Li, et al.
Published: (2016-11-01)

Third generation EGFR TKIs: current data and future directions
by: Chee-Seng Tan, et al.
Published: (2018-02-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
by: Marta Sesé, et al.
Published: (2019-08-01)

Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant  Gene Mutation in Advanced Lung Adenocarcinoma
by: Lijuan CHEN, et al.
Published: (2020-11-01)

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
by: Christi M. J. Steendam, et al.
Published: (2020-10-01)

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
by: Zhang Y, et al.
Published: (2018-12-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
by: Qing Zhou, et al.
Published: (2016-09-01)

A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for <i>EGFR</i> Mutations in Plasma from Non-Small Cell Lung Cancer Patients
by: Jung-Young Shin, et al.
Published: (2020-11-01)

Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis
by: Fei SU, et al.
Published: (2018-05-01)

Advanced Research on T790M Mutation in Non-small Cell Lung Cancer
by: Hui LI, et al.
Published: (2013-06-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
by: Yosuke Miyashita, et al.
Published: (2021-02-01)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
by: Zhao J, et al.
Published: (2018-09-01)

A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood
by: Shamini Selvarajah, PhD, et al.
Published: (2021-08-01)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
by: Naoki Haratake, MD, PhD, et al.
Published: (2020-11-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment
by: Xin Tang, et al.
Published: (2021-09-01)

Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer
by: Shanshan Ding, et al.
Published: (2019-10-01)

Simultaneous Detection of the T790M and L858R Mutations in the <i>EGFR</i> Gene by Oligoribonucleotide Interference-PCR
by: Keisuke Baba, et al.
Published: (2019-08-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Research Progress of the Resistance Mechanism of Non-small Cell Lung Cancer  to EGFR-TKIs
by: Huihui LIU, et al.
Published: (2013-10-01)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021-04-01)

Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer
by: HOU Ran, et al.
Published: (2020-06-01)

Performance of the Oncomine<sup>TM</sup> Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice
by: Giuseppa De Luca, et al.
Published: (2020-04-01)

Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAFV600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report
by: Ding H, et al.
Published: (2020-08-01)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
by: Hardy Niu, et al.
Published: (2017-09-01)